Efficacy and safety of FOLFOX biweekly cetuximab as first-line therapy for patients with nonresectable metastatic colorectal cancer (CELINE trial): Multicenter phase II trial.
Ken Kondo
No relevant relationships to disclose
Masanori Kotake
No relevant relationships to disclose
Kenji Doden
No relevant relationships to disclose
Yoshinori Munemoto
No relevant relationships to disclose
Kenji Kobayashi
No relevant relationships to disclose
Genichi Nishimura
No relevant relationships to disclose
Kazuhiko Omote
No relevant relationships to disclose
Junichi Sakamoto
No relevant relationships to disclose